Overview
Our Approach
Community Involvement
Overview
Sheila Mikhail
Jennifer Anderson
Timothy Ferguson
Fred Johnson
Overview
BioFuels
Clinical Trials
Due Diligence
Entrepreneurial Services
Intellectual Property Management
Joint Ventures and Strategic Alliances
Mergers and Acquisitions
Reduction of Costs
Technology Transfers & Licensing
Venture Capital Financing
Overview
LSL Articles and Presentations
Research Triangle Resources
Entrepreneurial Resources
Life Sciences & Technology Resources
Firm News
Client News
Contact Us
Driving Directions
Recruiting

Financing / Venture Capital

In the current tough funding environment, companies need attorneys experienced with financing transactions. Life Sciences Law attorneys have regularly represented companies, founders, venture capital firms, banks and investment banks in connection with investments in a life sciences company. These investments have ranged from start-up capital to private offerings of both equity and debt securities for established companies to initial public offerings. We have also assisted companies in structuring and obtaining research grants from governmental agencies and non-profit organizations.

Recent venture capital transactions, worth on aggregate of approximately $200 million, include:
  • Series A Convertible Preferred Stock in a company processing health insurance claims
  • Series A Convertible Preferred Stock in a company specializing in genetically reengineered pest control resistant crops;
  • Series A Convertible Preferred Stock in a company developing specialty drug products;
  • Series A Preferred Stock in company selling used laboratory and telecommunications equipment;
  • Series B Preferred Stock in a company developing an expert system for the management of treatments for HIV;
  • Series B Convertible Preferred Stock in a chemistry analysis and testing biotechnology company;
  • Series B Preferred Stock in a research services company
  • Series A and B Convertible Preferred in a company developing a treatment for heart failure
  • Series A and B Convertible Preferred in a company developing therapeutics for hemophilia and other bleeding disorders
  • Sale of a profits interest in a rFIX drug
  • Sales of convertible notes as bridge financing
  • Completion of several transactions with venture philanthropists, including the Muscular Dystrophy Association, the Musculoskeletal Transplant Foundation and the ALS Foundation

©2013 Life Sciences Law